BIOPHARMA
By
Can GSK’s Gepotidacin Priority FDA Review and Strategic Acquisitions Accelerate Its Antibiotic and Specialty Medicine Leadership in 2025?
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
Why Is Eli Lilly’s 2025 Outlook Soaring Despite Orforglipron’s Late-Stage Trial Falling Short?
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R Inhibition, Revolutionize Treatment for Sjögren’s Disease?
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug Price Cuts Signal a New Era of Affordable Innovation and Domestic Manufacturing?
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine the Future of Parkinson’s and Synucleinopathies?
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…
Could Servier’s $450M Fragile X Acquisition Redefine Its Neurology Strategy?
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
